Clinical-stage biopharma company developing inhalation drug delivery therapies and next-generation, direct-to-lung therapeutics
AUSTIN, Texas--(BUSINESS WIRE)--Nov. 19, 2019--
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, announced today that is has selected LaVoieHealthScience (LHS) as its investor relations and corporate communications Agency of Record. LHS is an integrated investor relations and strategic communications agency focused on helping clients advance their health and science innovations. TFF Pharmaceuticals is partnering with LHS to develop investor and media awareness of the Company as it prepares to introduce its first two compounds into human clinical trials.
The company’s proprietary Thin Film Freezing (TFF) platform addresses an important drug delivery limitation: that of poor water solubility and absorption. The TFF platform can signiﬁcantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide. The Company’s technology is particularly well suited to generate dry powder particles with properties enhanced for deep lung inhalation delivery. TFF Pharmaceuticals expects its dry powder formulations will minimize certain negative side effects that result from delivering these drugs systematically.
“As we move closer to the clinical trials stage and engage with partners, it’s critically important to build the right reputation among key stakeholders. LHS, with its proven track record in providing investor relations and integrated communications for global health science innovators, will be a great long-term partner,” said Glenn Mattes, President and CEO of TFF Pharmaceuticals. “LHS stood out with its understanding of our technology and value proposition across targeted channels and audiences, its team of high-touch senior communicators, and its proprietary approach to creating targeted messaging mapped to stakeholders as the foundation of a strategic IR and communications program. We are looking forward to a long and productive relationship.”
Donna L. LaVoie, President & CEO of LHS commented, “We are delighted to be working with TFF Pharmaceuticals to build investor and media visibility for the Company and for their pioneering Thin Film Freezing platform. We look forward to supporting the TFF Pharmaceuticals team as they continue to develop their pipeline and partnership opportunities.”
About TFF Pharmaceuticals
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tac-Lac Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 39 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com.
LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications, access and marketing. The firm provides investor relations, public relations and marketing consulting to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest-Growing Private Companies, ranked on the O’Dwyer’s list of 2019 Healthcare Public Relations Firms, PR Week’s list of 2019 Top Agencies and Boston Business Journal’s list of Largest Public Relations Firms in Massachusetts.
This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the Company’s plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) no drug product incorporating the TFF Platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (ii) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform and (iii) those other risks disclosed in the section “Risk Factors” included in the Company’s prospectus dated October 24, 2019 filed with the SEC on October 25, 2019. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119006018/en/
Source: TFF Pharmaceuticals, Inc.